Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Lockheed Wins $99M Contract To Support Production Of JASSM

Published 08/14/2019, 10:36 PM
Updated 07/09/2023, 06:31 AM

Lockheed Martin Corp. (NYSE:LMT) has received a contract to provide foreign military sales production support for Joint Air-to-Surface Standoff Missile (JASSM). Work related to the deal will be executed in Orlando, FL.

Valued at $99 million, the contract was awarded by the Air Force Life Cycle Management Center, Eglin Air Force Base, Florida. Per the terms of the agreement, Lockheed Martin will provide lifecycle support for all efforts related to JASSM and any JASSM variants in the areas of system upgrades, integration, production, sustainment, management and logistical support.

The contract is scheduled to be completed by August 2024 and will serve the nations of Finland, Poland and Australia.

A Brief Note on JASSM

The JASSM is a long range, conventional, stealthy, air-launched ground attack cruise missile designed for the Air Force and international partners with a range of 223-621.4 miles. JASSM was designed to destroy high-value, well-defended, fixed and re-locatable targets. The threshold integration aircraft were the F-16, B-52, and F/A-18 E/F.

The airframe design was to be compatible with all intended JASSM launch platforms — the B-52H, F-16C/D, F/A-18E/F, F-15E, F-117, B-1B, B-2, P-3C and S-3B.

What’s Favoring Lockheed Martin?

Increasing geopolitical and socioeconomic turmoil worldwide has prompted nations, both developed and developing, to expand the respective military arsenal with missiles constituting a significant portion of that inventory.

As one of the major missile makers in the United States, Lockheed Martin stands out among its peers by virtue of its broadly-diversified programs and strong order bookings. In second-quarter 2019, revenues at its Missiles and Fire Control unit came in at $2.41 billion, increasing 16% year over year, driven by higher sales for the tactical and strike missiles programs plus the sensors and global sustainment programs. At the end of the second quarter, this segment has a solid backlog of $26.2 billion.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Looking Ahead

The global rocket and missile market, which also includes fleet ballistic missiles, is projected to witness a CAGR of 4.74% during the 2017-2022 period to reach a value of $70 billion by 2022 (as per Markets and Markets research firm).

Such projections reflect increased growth opportunities for major missile-players like Lockheed Martin, Raytheon (NYSE:RTN) , Northrop Grumman (NYSE:NOC) and Boeing (NYSE:BA) in the aforementioned market.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Northrop Grumman Corporation (NOC): Free Stock Analysis Report

Lockheed Martin Corporation (LMT): Free Stock Analysis Report

The Boeing Company (BA): Free Stock Analysis Report

Raytheon Company (RTN): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.